delivering Doxorubicin payload is now possible with a precision targeting. Check out NAVB
Macrophage Therapeutics, Inc., a subsidiary of Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today announced that preclinical results in Kaposi’s Sarcoma (KS) demonstrated that a cytotoxic drug, doxorubicin, linked to Manocept™ was targeted to and dose-dependently taken up in CD206+ KS tumor cells and tumor associated macrophages (TAMs) and caused apoptotic death of the KS tumor cells and TAMs. The results are being presented at the 18th International Workshop on Kaposi's Sarcoma Herpesvirus (KSHV) and Related Agents in Hollywood, Florida by Michael S. McGrath, M.D., Ph.D., Professor, Departments of Laboratory Medicine, Pathology, and Medicine at the University of California, San Francisco (UCSF). The study also shows that Cy3-Manocept and a Cy3-Manocept-doxorubicin conjugate quantitatively permitted the evaluation of tumor burden, tissue uptake of Manocept and tumor response to therapy in vitro and ex vivo, supporting the potential for the Manocept platform to be used not only diagnostically but as a precision targeted molecule to deliver payloads to tumor sites throughout the body.
Its more serious than that. A anti depressant only numbs the reality. I'm afraid this is akin to still perfecting the crank up phone.. Hello Mable get me Mr. putznik
bunker bomb for disease. If this works out it will be a block buster platform. Buy here and save for your nice, I mean very nice retirement! This is a potential multi billion dollar opportunity. Sit back and watch the progress unfold. BIND has some other very impressive partnerships BIND is no second tier wannabe It is a diamond in the rough ... just like NAVB
The tide is turning. Its about party time long timers
Don't trust those valuations. They blow up if phase 3 fails or so on and so on. They have no better insight than you on the outcome. Phase 2 is only one step on a long journey to approval. Unless you have money to lose never hold thru announcements NEVER This is a nugget of very valuable wisdom. TV
It will hurt a little but wont kill you unless that is you gio head first
by the end of 1Q 2016 income will be about 5m and burn needs to be no more than 4m Is that possible?
what am I missing?
1Q 2016 the most important highlights from the report. Navidea is right on track. Forget the pie in the sky projections from a couple years ago. Stop looking in the rear view mirror. Lessons learned and appropriate action is being taken .Ramp up is slower than expected but is now getting a sure footing. The days of uncertainty are behind us. No more reruns TV
For now I'm holding if for no other reason to keep me humble. This is a fools game by many metrics. I'm the fool who played the game. Selling now would only allow me to find another sink hole and I'm done with that..